Dubermatinib clinical trials
Also written TP-0903.
How each study uses dubermatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dubermatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Sumitomo Pharma America, Inc. (2) · Uma Borate (1) · Beat AML, LLC (1)
Often tested with
Tested in the same studies.
Samalizumab (1) · BI 836858 (1) · Cytarabine (1) · Azacitidine (1) · Enasidenib (1) · Entospletinib (1) · Pevonedistat (1) · Ivosidenib (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses dubermatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as TP-0903 (BAML-16-001-S14)How we know
- First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid TumorsCompletedPhase 1Sumitomo Pharma America, Inc.NCT02729298Written as TP-0903How we know
- Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLLTerminatedPhase 1/2Sumitomo Pharma America, Inc.NCT03572634Written as TP-0903How we know
- TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid LeukemiaCompletedEarly Phase 1Uma BorateNCT04518345Written as DubermatinibHow we know
Codes
What other systems call dubermatinib · ClinicalTrials.gg INT000425
- MeSH (NLM) C000606144dubermatinibOne source NLM
- UNII (FDA) 14D65TV20JDUBERMATINIBConfirmed FDA, NLM
- NCI Thesaurus C127116DubermatinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000606144 | dubermatinib | One source NLM |
| UNII (FDA) | 14D65TV20J | DUBERMATINIB | Confirmed FDA, NLM |
| NCI Thesaurus | C127116 | Dubermatinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.